We are analyzing https://link.springer.com/article/10.1007/s40121-023-00913-y.

Title:
Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches | Infectious Diseases and Therapy
Description:
In 1976 Ebola revealed itself to the world, marking the beginning of a series of localized outbreaks. However, it was the Ebola outbreak that began in 2013 that incited fear and anxiety around the globe. Since then, our comprehension of the virus has been steadily expanding. Ebola virus (EBOV), belonging to the Orthoebolavirus genus of the Filoviridae family, possesses a non-segmented, negative single-stranded RNA genome comprising seven genes that encode multiple proteins. These proteins collectively orchestrate the intricate process of infecting host cells. It is not possible to view each protein as monofunctional. Instead, they synergistically contribute to the pathogenicity of the virus. Understanding this multifaceted replication cycle is crucial for the development of effective antiviral strategies. Currently, two antibody-based therapeutics have received approval for treating Ebola virus disease (EVD). In 2022, the first evidence-based clinical practice guideline dedicated to specific therapies for EVD was published. Although notable progress has been made in recent years, deaths still occur. Consequently, there is an urgent need to enhance the therapeutic options available to improve the outcomes of the disease. Emerging therapeutics can target viral proteins as direct-acting antivirals or host factors as host-directed antivirals. They both have advantages and disadvantages. One way to bypass some disadvantages is to repurpose already approved drugs for non-EVD indications to treat EVD. This review offers detailed insight into the role of each viral protein in the replication cycle of the virus, as understanding how the virus interacts with host cells is critical to understanding how emerging therapeutics exert their activity. Using this knowledge, this review delves into the intricate mechanisms of action of current and emerging therapeutics.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Video & Online Content
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, viral, virus, ebov, article, ebola, google, scholar, host, cas, central, evd, replication, protein, disease, infection, cell, transcription, rna, genome, entry, proteins, drug, antiviral, treatment, drugs, fusion, npc, cells, budding, membrane, therapeutics, approved, activity, inhibitors, cellular, polymerase, antivirals, viruses, zmapp, factors, repurposing, ebolavirus, patients, immune, potential, ibs, binding, group, complex,

Topics {✒️}

eu/en/medicines/human/orphan-designations/eu3151480 eu/en/medicines/human/orphan-designations/eu-3-18-2027 /en/pharma/african-sleeping-sickness gov/drugs/development-approval-process-drugs/drug-approvals host n-acetylglucosamine-1-phosphate transferase org/rare-diseases/niemann-pick-disease-type end=2020&start=1970&type=shaded&view=chart int/iris/bitstream/handle/10665/325000/9789241515894-eng antinucleoside n-phosphonacetyl-l-aspartate /contents/society-guideline-links-infection-control search=ebola&topicref=113258&source=see_link ebola virus—statpearls—ncbi bookshelf serine-arginine protein kinase 1 z-fa-fmk inhibits cathepsins s-adenosyl-homocysteine hydrolase inhibitors pre-sgp/pre-gp/pre-ssgp recombinant dna technology n-phosphonacetyl-l-aspartate host-directed antiviral therapy recombinant purified gp1 called multi-antibody approach gov/drugsatfda_docs/label/2020/761172s000lbl nuclear transporter karyopherin-α antibody-dependent complement deposition c-type lectin domain article almeida-pinto host low-ph-dependent cathepsins pi3k-akt-rac1 pathway niemann-pick c1 receptor niemann-pick disease type endolysosomal niemann-pick c1 s-adenosyl-homocysteine hydrolase pre-ssgp undergoes maturation generating s-adenosyl homocysteine niemann-pick c1 compartments inhibit hmg-coa reductase antibody-dependent cellular cytotoxicity amp-activated protein kinase eu/en/medicines disulfide-linked gp1–gp2 heterodimers rt-qpcr-confirmed evd host xk-related protein eukaryotic initiation factor 4a positive-strand rna genomes article download pdf francisca almeida-pinto nonstructural virus-encoded protein rui pinto declare small c-terminal domain european medicines agency

Questions {❓}

Ebanga™ and Inmazeb®: A Perfect Combination?
Com/contents/society-guideline-links-infection-control?
Global/files/proposals/approved?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches
         description:In 1976 Ebola revealed itself to the world, marking the beginning of a series of localized outbreaks. However, it was the Ebola outbreak that began in 2013 that incited fear and anxiety around the globe. Since then, our comprehension of the virus has been steadily expanding. Ebola virus (EBOV), belonging to the Orthoebolavirus genus of the Filoviridae family, possesses a non-segmented, negative single-stranded RNA genome comprising seven genes that encode multiple proteins. These proteins collectively orchestrate the intricate process of infecting host cells. It is not possible to view each protein as monofunctional. Instead, they synergistically contribute to the pathogenicity of the virus. Understanding this multifaceted replication cycle is crucial for the development of effective antiviral strategies. Currently, two antibody-based therapeutics have received approval for treating Ebola virus disease (EVD). In 2022, the first evidence-based clinical practice guideline dedicated to specific therapies for EVD was published. Although notable progress has been made in recent years, deaths still occur. Consequently, there is an urgent need to enhance the therapeutic options available to improve the outcomes of the disease. Emerging therapeutics can target viral proteins as direct-acting antivirals or host factors as host-directed antivirals. They both have advantages and disadvantages. One way to bypass some disadvantages is to repurpose already approved drugs for non-EVD indications to treat EVD. This review offers detailed insight into the role of each viral protein in the replication cycle of the virus, as understanding how the virus interacts with host cells is critical to understanding how emerging therapeutics exert their activity. Using this knowledge, this review delves into the intricate mechanisms of action of current and emerging therapeutics.
         datePublished:2024-01-19T00:00:00Z
         dateModified:2024-01-19T00:00:00Z
         pageStart:21
         pageEnd:55
         license:http://creativecommons.org/licenses/by-nc/4.0/
         sameAs:https://doi.org/10.1007/s40121-023-00913-y
         keywords:
            EBOV
            Emerging therapeutics
            EVD
            Mechanism of action
            Pharmacology
            Replication cycle
            Repurposing
            Review
            Virology
            Internal Medicine
            Infectious Diseases
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig6_HTML.png
         isPartOf:
            name:Infectious Diseases and Therapy
            issn:
               2193-6382
               2193-8229
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Francisca Almeida-Pinto
               url:http://orcid.org/0009-0000-8560-3377
               affiliation:
                     name:Universidade de Lisboa
                     address:
                        name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Rui Pinto
               url:http://orcid.org/0000-0002-1667-7871
               affiliation:
                     name:Universidade de Lisboa
                     address:
                        name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
                        type:PostalAddress
                     type:Organization
                     name:Research Institute for Medicines (iMED.ULisboa)
                     address:
                        name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
                        type:PostalAddress
                     type:Organization
                     name:Joaquim Chaves Saúde (JCS)
                     address:
                        name:Dr. Joaquim Chaves, Medicine Laboratory, Joaquim Chaves Saúde (JCS), Carnaxide, Portugal
                        type:PostalAddress
                     type:Organization
               type:Person
               name:João Rocha
               url:http://orcid.org/0000-0002-0303-8085
               affiliation:
                     name:Universidade de Lisboa
                     address:
                        name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
                        type:PostalAddress
                     type:Organization
                     name:Research Institute for Medicines (iMED.ULisboa)
                     address:
                        name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches
      description:In 1976 Ebola revealed itself to the world, marking the beginning of a series of localized outbreaks. However, it was the Ebola outbreak that began in 2013 that incited fear and anxiety around the globe. Since then, our comprehension of the virus has been steadily expanding. Ebola virus (EBOV), belonging to the Orthoebolavirus genus of the Filoviridae family, possesses a non-segmented, negative single-stranded RNA genome comprising seven genes that encode multiple proteins. These proteins collectively orchestrate the intricate process of infecting host cells. It is not possible to view each protein as monofunctional. Instead, they synergistically contribute to the pathogenicity of the virus. Understanding this multifaceted replication cycle is crucial for the development of effective antiviral strategies. Currently, two antibody-based therapeutics have received approval for treating Ebola virus disease (EVD). In 2022, the first evidence-based clinical practice guideline dedicated to specific therapies for EVD was published. Although notable progress has been made in recent years, deaths still occur. Consequently, there is an urgent need to enhance the therapeutic options available to improve the outcomes of the disease. Emerging therapeutics can target viral proteins as direct-acting antivirals or host factors as host-directed antivirals. They both have advantages and disadvantages. One way to bypass some disadvantages is to repurpose already approved drugs for non-EVD indications to treat EVD. This review offers detailed insight into the role of each viral protein in the replication cycle of the virus, as understanding how the virus interacts with host cells is critical to understanding how emerging therapeutics exert their activity. Using this knowledge, this review delves into the intricate mechanisms of action of current and emerging therapeutics.
      datePublished:2024-01-19T00:00:00Z
      dateModified:2024-01-19T00:00:00Z
      pageStart:21
      pageEnd:55
      license:http://creativecommons.org/licenses/by-nc/4.0/
      sameAs:https://doi.org/10.1007/s40121-023-00913-y
      keywords:
         EBOV
         Emerging therapeutics
         EVD
         Mechanism of action
         Pharmacology
         Replication cycle
         Repurposing
         Review
         Virology
         Internal Medicine
         Infectious Diseases
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40121-023-00913-y/MediaObjects/40121_2023_913_Fig6_HTML.png
      isPartOf:
         name:Infectious Diseases and Therapy
         issn:
            2193-6382
            2193-8229
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Francisca Almeida-Pinto
            url:http://orcid.org/0009-0000-8560-3377
            affiliation:
                  name:Universidade de Lisboa
                  address:
                     name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Rui Pinto
            url:http://orcid.org/0000-0002-1667-7871
            affiliation:
                  name:Universidade de Lisboa
                  address:
                     name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
                     type:PostalAddress
                  type:Organization
                  name:Research Institute for Medicines (iMED.ULisboa)
                  address:
                     name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
                     type:PostalAddress
                  type:Organization
                  name:Joaquim Chaves Saúde (JCS)
                  address:
                     name:Dr. Joaquim Chaves, Medicine Laboratory, Joaquim Chaves Saúde (JCS), Carnaxide, Portugal
                     type:PostalAddress
                  type:Organization
            type:Person
            name:João Rocha
            url:http://orcid.org/0000-0002-0303-8085
            affiliation:
                  name:Universidade de Lisboa
                  address:
                     name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
                     type:PostalAddress
                  type:Organization
                  name:Research Institute for Medicines (iMED.ULisboa)
                  address:
                     name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Infectious Diseases and Therapy
      issn:
         2193-6382
         2193-8229
      volumeNumber:13
Organization:
      name:Springer Healthcare
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Universidade de Lisboa
      address:
         name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
         type:PostalAddress
      name:Universidade de Lisboa
      address:
         name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
         type:PostalAddress
      name:Research Institute for Medicines (iMED.ULisboa)
      address:
         name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
         type:PostalAddress
      name:Joaquim Chaves Saúde (JCS)
      address:
         name:Dr. Joaquim Chaves, Medicine Laboratory, Joaquim Chaves Saúde (JCS), Carnaxide, Portugal
         type:PostalAddress
      name:Universidade de Lisboa
      address:
         name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
         type:PostalAddress
      name:Research Institute for Medicines (iMED.ULisboa)
      address:
         name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Francisca Almeida-Pinto
      url:http://orcid.org/0009-0000-8560-3377
      affiliation:
            name:Universidade de Lisboa
            address:
               name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Rui Pinto
      url:http://orcid.org/0000-0002-1667-7871
      affiliation:
            name:Universidade de Lisboa
            address:
               name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
               type:PostalAddress
            type:Organization
            name:Research Institute for Medicines (iMED.ULisboa)
            address:
               name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
               type:PostalAddress
            type:Organization
            name:Joaquim Chaves Saúde (JCS)
            address:
               name:Dr. Joaquim Chaves, Medicine Laboratory, Joaquim Chaves Saúde (JCS), Carnaxide, Portugal
               type:PostalAddress
            type:Organization
      name:João Rocha
      url:http://orcid.org/0000-0002-0303-8085
      affiliation:
            name:Universidade de Lisboa
            address:
               name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
               type:PostalAddress
            type:Organization
            name:Research Institute for Medicines (iMED.ULisboa)
            address:
               name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
      name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
      name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
      name:Dr. Joaquim Chaves, Medicine Laboratory, Joaquim Chaves Saúde (JCS), Carnaxide, Portugal
      name:Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal
      name:Laboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal

External Links {🔗}(604)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Leaflet
Particles.js
Prism.js

CDN Services {📦}

Crossref

5.95s.

LINK . SPRINGER . COM {}